Stay updated on Venetoclax Combo vs Low Dose Cytarabine in AML Clinical Trial
Sign up to get notified when there's something new on the Venetoclax Combo vs Low Dose Cytarabine in AML Clinical Trial page.

Latest updates to the Venetoclax Combo vs Low Dose Cytarabine in AML Clinical Trial page
- ChecktodayNo Change Detected
- Check7 days agoChange DetectedThe page’s revision label was updated from **Revision: v3.5.2** to **Revision: v3.5.3**.SummaryDifference0.0%

- Check15 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check22 days agoNo Change Detected
- Check43 days agoChange DetectedAdded Revision: v3.5.0 and removed Revision: v3.4.3 from the page.SummaryDifference0.0%

- Check51 days agoChange DetectedDeleted the citation for Wei AH et al. on risk stratification of low-dose cytarabine and venetoclax in AML (Blood Advances, 2026).SummaryDifference0.0%

- Check58 days agoChange DetectedAdded Revision v3.4.3 and removed Revision v3.4.2.SummaryDifference0.0%

- Check65 days agoChange DetectedA new Blood Advances 2026 publication citation is added to the Publications section, and the 2025 ahead-of-print citation is removed.SummaryDifference0.0%

Stay in the know with updates to Venetoclax Combo vs Low Dose Cytarabine in AML Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Venetoclax Combo vs Low Dose Cytarabine in AML Clinical Trial page.